Séverine is the Vice President of Mammalian Cell Line Development (CLD) at KBI Biopharma’s Geneva Facility. Prior to the operational consolidation with KBI, Séverine held multiple leadership roles with escalating responsibilities at Selexis. She brings nearly two decades of experience in the pharmaceutical industry, and deep expertise in early drug discovery, antibody engineering (bispecifics), stable cell line development, and project management.
Séverine holds a master’s in biotechnology from L’Ecole Nationale Supérieure de Technologie des Biomolécules de Bordeaux (ENSTBB) and a PhD in protein engineering from University of Geneva, acquired through NovImmune (now Light Chain Bioscience). She subsequently held a postdoctoral position at the University of Geneva where she designed a novel phage display platform for accelerating bispecific antibody development.
